Weekly Life Science News Round-Up: 28th March – 1st April

A round-up of the latest news from the Life Science industry; including Clinical Research, Pharmaceutical and Biotechnology news from 28^th March – 1^st April.

Technovalia, Sypharma and BioNet announce the establishment of Genetis, the first Australian vaccine development and manufacturing hub for mRNA, DNA and recombinant vaccines.

Establishment of the first end-to-end Australian capability for product development and commercial scale production of mRNA, DNA and recombinant vaccines.

Sanofi and IGM Biosciences announce collaboration agreement for oncology, immunology and inflammation targets.

Sanofi and IGM Biosciences announce an exclusive worldwide collaboration agreement to create, develop, manufacture, and commercialize IgM antibody agonists against three oncology targets and three immunology/inflammation targets.

Thermo Fisher Scientific launches CE-IVD marked next-generation sequencing instrument for use in clinical labs.

Thermo Fisher Scientific launch the CE-IVD marked Ion Torrent Genexus Dx Integrated Sequencer, an automated, next-generation sequencing (NGS) platform that delivers results in as little as a single day.

Abbott and LISC team up to address diversity and equity gaps in the healthcare industry supply chain.

Abbott and the Local Initiatives Support Corporation (LISC) announced a $37.5 million initiative to provide diverse small businesses with the tailored growth capital, loans and support they need to compete, grow and create jobs.

ViiV Healthcare announces US FDA approval of Triumeq PD, the first dispersible single tablet regimen containing dolutegravir, a once-daily treatment for children living with HIV.

ViiV Healthcare has announced that the U.S. Food and Drug Administration (FDA) has approved a new drug application (NDA) for a dispersible tablet formulation of the fixed dose combination of abacavir, dolutegravir and lamivudine for the treatment of pediatric patients weighing 10kgs to <25 kgs with human immunodeficiency virus type 1 (HIV-1).

HCL Technologies expands global partnership with Novo Nordisk.

HCL Technologies has been selected to provide global service desk and on-site support to Novo Nordisk.

SYNLAB partners with OncoDNA to provide comprehensive biomarker testing for cancer therapy selection in Germany.

SYNLAB and OncoDNA announce a partnership to provide oncologists with the high-quality, pan-cancer OncoDEEP(R) biomarker test in Germany.

Accelerate Diagnostics announces launch of Accelerate Arc™ module and BC kit.

Accelerate Diagnostics announce the launch of the Accelerate Arc system, an automated path to rapid and accurate microbial identification for positive blood cultures.

DelSiTech enters into an exclusive licensing agreement with Optifye Therapeutics for the development of a controlled release ophthalmic eye drop product.

DelSiTech and Optifye Therapeutics AG announce an exclusive licensing agreement pertaining to the development of controlled-release dexamethasone eye drops utilizing DelSiTech™ Silica Matrix technology.

Rejuvenate Biomed started a groundbreaking clinical trial and expands for future growth.

Rejuvenate Biomed provides an update on its development pipeline and strategy.

Scenic Biotech and the Barth Syndrome Foundation announce partnership to explore genetic modifiers to find a tailored treatment for the complex rare disease.

Scenic Biotech and the Barth Syndrome Foundation (BSF of ‘the Foundation’) announce they have entered into a partnership to support the advancement of Scenic’s in-house drug discovery program.

Iktos announces a collaboration with Ono in artificial intelligence for new drug design.

Iktos announce a collaboration agreement with Ono Pharmaceuticals Co., Ltd, a leading pharmaceutical company based in Japan with a focus on innovative medicines dedicated to the fight against disease and pain.

Bayer set to drive breakthrough innovations in the life sciences.

Bayer holds its first ever Breakthrough Innovation Forum, focusing on longer-term opportunities for health and agriculture leveraging emerging technologies.

Labcorp renews strategic partnership with Medidata to provide suite of clinical trial technologies and services.

Labcorp has selected Medidata’s technology platform to extend their 14-year partnership, the foundation of their initiative to co-develop digital biomarkers and expand the use and functionality of decentralized clinical trials.

-

See more of the latest news on PharmiWeb.com and PharmiWeb.Jobs.